Navigation Links
Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
Date:2/23/2010

PALO ALTO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its fourth quarter and full year 2009 financial results and discuss 2010 financial guidance on Wednesday, March 3, 2010. Jazz Pharmaceuticals will host an investor conference call and live webcast to give a company update, as well as to discuss financial results and guidance, on March 3, 2010, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceuticals' website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through March 17, 2010.

Investors may participate in the conference call by dialing 1-800-591-6923 in the U.S., or 1-617-614-4907 outside the U.S., and entering passcode 79845734.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

SOURCE Jazz Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.jazzpharmaceuticals.com

'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... Recognising that in today’s busy world consumers are often ... in just three weeks. Setting the groundwork for a healthier lifestyle, Leany Greeny ... work and family schedules, participants can lose up to 15lbs during the program ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Houston, Texas, ... team took Friday, September 8, and Monday, September 11, off work and rolled up ... Baptist Church before heading to local homes to start the process of rebuilding. , ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... ... , ... Only a few physicians were selected to receive the prestigious 2016 ... MD, FACS . The founder and medical director of Clevens Face and Body ... Yale, Harvard and the University of Michigan. He has served patients throughout Central Florida ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter Chandonait, Abt Associates Principal ... Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , has been named the ... to Action Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners ...
Breaking Medicine News(10 mins):